Not available
Quote | Athenex Inc. (NASDAQ:ATNX)
Last: | $0.2031 |
---|---|
Change Percent: | 17.01% |
Open: | $0.22 |
Close: | $0.2031 |
High: | $0.2571 |
Low: | $0.2016 |
Volume: | 1,712,513 |
Last Trade Date Time: | 05/24/2023 03:00:00 am |
News | Athenex Inc. (NASDAQ:ATNX)
2023-05-15 13:13:19 ET Gainers: Ohmyhome Limited ( OMH ) +169% . NeoGames ( NGMS ) +112% . GSI Technology ( GSIT ) +36% . Vaxart ( VXRT ) +34% . WiSA Technologies ( WISA ) +35% . Scilex Holding Company ( SCLX ) +31% ....
2023-05-15 08:24:37 ET Athenex ( ATNX ) -60% after bankruptcy filing . Larimar Therapeutics ( LRMR ) -34% reports preliminary top-line data from phase 2 trial’s 25 mg cohort showing increases in frataxin levels in patients with Friedreich’s Ataxia...
Message Board Posts | Athenex Inc. (NASDAQ:ATNX)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ATNX News Article - Quantum Leap Healthcare Collaborative Announces Result of Oral Pac | whytestocks | investorshangout | 05/01/2023 5:20:47 PM |
What I say now, is I'm still laughing | trendzone | investorshub | 02/21/2023 4:17:18 PM |
what you say now? | posilock | investorshub | 02/21/2023 3:05:19 AM |
whytestocks: $ATNX News Article - Penny Stocks To Buy? 3 Stocks Under $1 To Watch Now | whytestocks | investorshangout | 01/05/2023 7:45:46 PM |
Short pigs getting setup for after hours squeeze | trendzone | investorshub | 01/03/2023 7:59:35 PM |
News, Short Squeeze, Breakout and More Instantly...
Athenex Inc. Company Name:
ATNX Stock Symbol:
NASDAQ Market:
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (...
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO PR Newswire SAN FRANCISCO , May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and At...
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $1...